JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

NVS

152.1

+0.44%↑

Home・Akciju saraksts・Eli Lilly and Co.

Eli Lilly and Co.

Atvērts

SektorsVeselības aprūpe

1,066.82 2.48

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1064.22

Max

1070.02

Galvenie mērījumi
By Trading Economics
Ienākumi	758M 7.4B
Pārdošana	507M 20B
P/E Sektora vidējais	35.088 49.701
EPS	8.55
Dividenžu ienesīgums	0.62
Peļņas marža	37.355
Darbinieki	50,000
EBITDA	971M 9.4B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+18.99% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.62% 2.39%
Nākamie ieņēmumi	2026. g. 5. aug.
Nākamais dividenžu datums	2026. g. 10. jūn.
Nākamais Ex dividenžu datums	2026. g. 14. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	105B 881B
Iepriekšējā atvēršanas cena	1064.34
Iepriekšējā slēgšanas cena	1066.82

Ziņu noskaņojums

By Acuity

21%

79%

31 / 345 Rangs Healthcare

Eli Lilly and Co. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. maijs 14:24 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly Buys Engage Biologics for Up to $202 Million

2026. g. 30. apr. 12:01 UTC

Peļņas

Galvenie tirgus virzītāji

Eli Lilly Shares Jump On Guidance Boost, Earnings Above Expectations

2026. g. 20. maijs 13:35 UTC

Iegādes, apvienošanās, pārņemšana

Engage Bio: Eli Lilly Deal Includes Upfront, Milestone Payments >LLY

2026. g. 20. maijs 13:34 UTC

Iegādes, apvienošanās, pārņemšana

Engage Bio Acquired by Eli Lilly for Up to $202 Million >LLY

2026. g. 7. maijs 09:30 UTC

Peļņas

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

2026. g. 6. maijs 12:36 UTC

Peļņas

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

2026. g. 6. maijs 10:12 UTC

Peļņas

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

2026. g. 6. maijs 09:58 UTC

Peļņas

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

2026. g. 30. apr. 20:59 UTC

Karstas akcijas

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

2026. g. 30. apr. 20:12 UTC

Peļņas

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

2026. g. 30. apr. 16:43 UTC

Peļņas

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

2026. g. 30. apr. 16:10 UTC

Tirgus saruna

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

2026. g. 30. apr. 15:13 UTC

Peļņas

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

2026. g. 30. apr. 14:58 UTC

Peļņas

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

2026. g. 30. apr. 14:53 UTC

Peļņas

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

2026. g. 30. apr. 14:50 UTC

Peļņas

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

2026. g. 30. apr. 14:42 UTC

Peļņas

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

2026. g. 30. apr. 14:39 UTC

Peļņas

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

2026. g. 30. apr. 14:35 UTC

Peļņas

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

2026. g. 30. apr. 14:24 UTC

Peļņas

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

2026. g. 30. apr. 14:17 UTC

Peļņas

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

2026. g. 30. apr. 13:56 UTC

Peļņas

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

2026. g. 30. apr. 13:37 UTC

Karstas akcijas

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

2026. g. 30. apr. 12:32 UTC

Tirgus saruna

Peļņas

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

2026. g. 30. apr. 12:29 UTC

Tirgus saruna

Peļņas

Eli Lilly CEO Says Foundayo Adoption Could Take Time -- Market Talk

2026. g. 30. apr. 12:23 UTC

Tirgus saruna

Peļņas

Eli Lilly CEO Says International Demand for GLP-1s Is Ramping Up -- Market Talk

2026. g. 30. apr. 12:10 UTC

Peļņas

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

2026. g. 30. apr. 12:08 UTC

Peļņas

Eli Lilly Sales, Profits Surge on Weight-Loss Drugs -- WSJ

2026. g. 30. apr. 12:04 UTC

Tirgus saruna

Peļņas

Eli Lilly's GLP-1 Party Has No End in Sight -- Market Talk

2026. g. 30. apr. 11:39 UTC

Karstas akcijas

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

Salīdzinājums

Cenas izmaiņa

Eli Lilly and Co. Prognoze

Cenas mērķis

By TipRanks

18.99% augšup

Prognoze 12 mēnešiem

Vidējais 1,267.24 USD 18.99%

Augstākais 1,500 USD

Zemākais 850 USD

Pamatojoties uz 23 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Eli Lilly and Co. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

23 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 23 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Eli Lilly and Co. — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

31 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.